DNase-seq adapts traditional DNase I footprinting 1 and leverages modern DNA sequencing to identify regions of the genome where regulatory factors interact with DNA to modify chromatin structure and ...

New research has developed an immunotherapy for cancer by combining DNase I with CAR T-cell therapy. The research conducted by Xenetic Biosciences titled, "The synergistic action of DNase I and CAR T ...

JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company ...

More than 30% of patients with pleural infection either die or require surgery. Drainage of infected fluid is key to successful treatment, but intrapleural fibrinolytic therapy did not improve ...

Xenetic (XBIO) Biosciences announced the presentation of positive preclinical data. The poster titled, ” DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade ...

These days, for many of the species we study, it’s easy to get a sense of what is present in the DNA, as there are ever-expanding collections of genomes available to browse online. But looking at the ...

FRAMINGHAM, MA / ACCESSWIRE / July 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology ...

Systemic DNase I combined with 𝛼-CTLA-4 antibody demonstrated to promote antitumor immunity and generate immunological memory against microsatellite stable, mismatch repair proficient colorectal ...

Participants in a phase I/II clinical trial of a new enzyme-based treatment for severe dry eye disease experienced reduced signs of disease and discomfort, according to a paper in Translational Vision ...

Participants in a phase I/II clinical trial of a new enzyme-based treatment for severe dry eye disease experienced reduced signs of disease and discomfort, according to a paper in Translational Vision ...